PMP deadline approaching

February 6, 2020 Laura Hale Brockway

Beginning March 1, Texas physicians will be required to check the Texas Prescription Monitoring Program (PMP) before prescribing or dispensing opioids, benzodiazepines, barbiturates, or carisoprodol.

Physicians (or their delegates) must check each patient’s prescription history within the PMP for evidence of doctor-shopping or drug diversion. The law does not apply to physicians prescribing for patients diagnosed with cancer or patients receiving hospice care.

PMP accounts

The Texas State Board of Pharmacy manages the PMP and automatically creates PMP accounts based on information it receives from the Texas Medical Board. However, prescribers must manually finalize their accounts.

With your finalized account, you can find out if a patient is receiving Schedule II, III, IV, and V controlled substances. You can also receive email notifications when the system finds evidence of suspicious activity.

The Texas PMP can now be integrated into your electronic health records, allowing access to PMP data within your daily workflow. For more information about integrating the Texas PMP into your EHR system, visit txpmp.org/integration.

 

Using a delegate

At your discretion, you can delegate the task of checking the database to trusted staff. Once you are registered, you can assign medical staff to assist in querying the PMP. It is important that your delegate register for his or her own account in the system. Physicians should never share PMP log-in information with their staff or delegate.

In addition, physicians and staff should only query their own prescribing history or patients with whom they have an established relationship. Querying individuals who are not your patients is a violation of HIPAA.


Documentation

To show that you are in compliance with this new law, document in the patient’s chart that you have checked the PMP before prescribing opioids, benzodiazepines, barbiturates, carisoprodol. 

 

For more information

 

About the Author

Laura Hale Brockway is the Vice President of Marketing at TMLT. She can be reached at laura-brockway@tmlt.org.

Visit Website More Content by Laura Hale Brockway
Previous Article
New opioid prescribing limits take effect September 1
New opioid prescribing limits take effect September 1

New legislation places a 10-day limit on opioid prescriptions for acute pain.

Next Article
HHS guide for appropriate tapering or discontinuation of long-term opioid use
HHS guide for appropriate tapering or discontinuation of long-term opioid use

New guidance from the U.S. Department of Health and Human Services (HHS) provides clarification and advice ...